title: Correlation between carbapenem consumption and resistance to carbapenems among Enterobacteriaceae isolates collected from patients with intra-abdominal infections at five medical centers in Taiwan, 2006-2010.
abstract: We investigated the trend in resistance to carbapenems among isolates of Enterobacteriaceae that had been collected from patients with intra-abdominal infections at five medical centers in Taiwan from 2006 to 2010 and evaluated the correlation between resistance to carbapenems and consumption of said agents as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART). During the study period, the usage of ertapenem and that of total carbapenems (ertapenem, imipenem, and meropenem) increased significantly from 6.13 to 13.38 defined daily doses per 1000 patient-days for ertapenem and from 20.43 to 34.25 defined daily doses per 1000 patient-days for total carbapenems. The most common species were Escherichia coli (n = 1095), Klebsiella spp. (n = 663), and Enterobacter spp. (n = 202). The susceptibility of all isolates to ertapenem and to imipenem varied during the study period. For ertapenem, the rates of nonsusceptibility ranged from 3.5% to 10.3% and those for imipenem ranged from 3.5% to 10.7%. Although the use of carbapenems increased during the study period, there was no marked increase in resistance to carbapenems. Continuous monitoring of resistance trends is necessary so that antimicrobial prescription policies can be adjusted and infection control intervention programs can be implemented.
authors: Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
authors: Cheng-Mao
authors: CM
authors: Ho
authors: Mao-Wang
authors: MW
authors: Ho
authors: Yung-Ching
authors: YC
authors: Liu
authors: Han-Siong
authors: HS
authors: Toh
authors: Yu-Lin
authors: YL
authors: Lee
authors: Yuag-Meng
authors: YM
authors: Liu
authors: Chi-Chang
authors: CC
authors: Huang
authors: Po-Liang
authors: PL
authors: Lu
authors: Chun-Eng
authors: CE
authors: Liu
authors: Yen-Hsu
authors: YH
authors: Chen
authors: Wen-Chien
authors: WC
authors: Ko
authors: Hung-Jen
authors: HJ
authors: Tang
authors: Kwok-Woon
authors: KW
authors: Yu
authors: Yao-Shen
authors: YS
authors: Chen
authors: Yin-Ching
authors: YC
authors: Chuang
authors: Jen-Hsien
authors: JH
authors: Wang
authors: Po-Ren
authors: PR
authors: Hsueh
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D015780:Carbapenems / Q000494:pharmacology* / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000302:isolation & purification / Q000472:pathogenicity; D004756:Enterobacteriaceae Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D000077727:Ertapenem; D006801:Humans; D059413:Intraabdominal Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D016014:Linear Models; D000077731:Meropenem; D008826:Microbial Sensitivity Tests / Q000379:methods; D015995:Prevalence; D011446:Prospective Studies; D013624:Taiwan / Q000453:epidemiology; D013845:Thienamycins / Q000494:pharmacology / Q000627:therapeutic use; D047090:beta-Lactams / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D013845:Thienamycins; D047090:beta-Lactams; D000077731:Meropenem; D000077727:Ertapenem